Collegium Pharmaceutical, Inc. Noncash or Part Noncash Acquisition, Other Liabilities Assumed
Collegium Pharmaceutical, Inc. (COLL) reported Noncash or Part Noncash Acquisition, Other Liabilities Assumed of $254.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 · last filed 2021-02-25
- Collegium Pharmaceutical, Inc. noncash or part noncash acquisition, other liabilities assumed for the quarter ending 2018-12-31 was $0.00.
- Collegium Pharmaceutical, Inc. noncash or part noncash acquisition, other liabilities assumed for the quarter ending 2018-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. noncash or part noncash acquisition, other liabilities assumed for fiscal 2018 was $254.00K.
| Period end | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 3 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 6 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 9 month | Noncash or Part Noncash Acquisition, Other Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $254.00K 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $254.00K 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $254.00K 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |